Combining bioinformatics, network pharmacology and artificial intelligence to predict the mechanism of celastrol in the treatment of type 2 diabetes

Abstract

BackgroundType 2 diabetes (T2D) is a common chronic disease with many serious complications. Celastrol can prevent and treat type 2 diabetes by reversing insulin resistance in a number of ways. However, the specific mechanisms by which celastrol prevents and treats T2D are not well understood. The aim of this study was to explore the key gene targets and potential signaling pathway mechanisms of celastrol for the treatment of T2D.MethodsGSE184050 was downloaded from the Gene Expression Omnibus online database. Blood samples from patients and healthy individuals with T2D were analyzed to identify differentially expressed genes (DEGs), and a protein−protein interaction network (PPI) was constructed. Key gene analysis of DEGs was performed using the MCODE plugin in Cystoscope as well as the Hubba plugin, and intersections were taken to obtain hub genes, which were displayed using a Venn diagram. Enrichment analysis was then performed via the ClueGo plugin in Cytoscape and validated using Gene Set Enrichment Analysis. The therapeutic targets of celastrol were then analyzed by pharmacophore network pharmacology, intersected to identify the therapeutic targets of celastrol, enriched for all targets, and intersected to obtain the signaling pathways for celastrol treatment. The protein structures of the therapeutic targets were predicted using the artificial intelligence AlphaFold2. Finally, molecular docking was used to verify whether celastrol could be successfully docked to the predicted targets.Results618 DEGs were obtained, and 9 hub genes for T2D were identified by the MCODE and Hubba plug-ins, including ADAMTS15, ADAMTS7, ADAMTSL1, SEMA5B, ADAMTS8, THBS2, HBB, HBD and HBG2. The DEG-enriched signaling pathways mainly included the ferroptosis and TGF-beta signaling pathways. A total of 228 target genes were annotated by pharmacophore target analysis, and the therapeutic targets were identified, including S100A11, RBP3, HBB, BMP7 and IQUB, and 9 therapeutic signaling pathways were obtained by an intersectional set. The protein structures of the therapeutic targets were successfully predicted by AlphaFold2, and docking was validated using molecular docking.ConclusionCelastrol may prevent and treat T2D through key target genes, such as HBB, as well as signaling pathways, such as the TGF-beta signaling pathway and type II diabetes mellitus.

Uncovering lupus nephritis-specific genes and the potential of TNFRSF17-targeted immunotherapy: a high-throughput sequencing study

“…In addition, Wu et al. identified HBB as a major player in the iron death signaling pathway in diabetes ( 64 ). Sharma et al.…”

“…Afridi et al found that HBB polymorphisms upregulated the production of anti-malarial IgG (63). In addition, Wu et al identified HBB as a major player in the iron death signaling pathway in diabetes (64). Sharma et al also found HBB to be enriched in the iron homeostasis and iron death signaling pathways (65).…”

Targeting ferroptosis unveils a new era for traditional Chinese medicine: a scientific metrology study

“…Notably, AI has made substantial contributions to cancer research and precision medicine (Bhinder et al, 2021). Within the framework of ferroptosis, Wu et al employed a blend of bioinformatics and AI to posit that ferroptosis and the TGF-β signaling pathway potentially underpin the protective attributes of celastrol against type 2 diabetes (Wu and Zhang, 2022). In October 2023, Liu et al demonstrated the potential of deep-learning-assisted phenotypic screening to identify promising lead compounds for alleviating doxorubicin-induced cardiomyopathy by preventing ferroptosis (Liu C. et al, 2023).…”

Diabetes cardiomyopathy: targeted regulation of mitochondrial dysfunction and therapeutic potential of plant secondary metabolites

“…The results showed that celastrol (50 μg/kg/d) treatment for 4 weeks could downregulate the expression of P38 protein in the MAPK pathway, reverse the energy remodeling, mitochondrial dysfunction, and oxidative stress induced by STZ-induced SD diabetic rats, thereby delaying the deterioration of heart function and myocardial interstitial fibrosis. The study suggests that the MAPK signaling pathway may be an effective intervention target for DCM ( Wu et al, 2022 ). In another study, celastrol can also alleviate diabetes-induced cardiac damage, inhibit mitochondrial ROS production, and suppress the release of inflammatory factors.…”